Krzystyniak K, Desjardins R, Thérien H M, Banska W, Tancrede P, Descotes J
Départment des Sciences Biologiques, Université du Québec à Montréal, Canada.
Int J Immunopharmacol. 1994 Oct;16(10):817-24. doi: 10.1016/0192-0561(94)90055-8.
The lymphoproliferative potential of liposome-trapped streptoztocin (STZ) was compared to the effect of saline-dissolved STZ injected locally into the foot pad of CD-1 mice. Popliteal lymph node (PLN) enlargement and early cell activation of lymphocyte subsets were monitored during the onset of STZ-induced autoimmune-like reaction. Injection of the optimal STZ dose, 0.5 mg/foot pad, markedly increased the absolute PLN cell number as well as specific T-helper (CD4+), T-suppressor/cytotoxic (CD8+), and B-(Ig+) cell subsets stained with fluorescent monoclonal antibodies. Furthermore, there was a marked increase in the number of large/activated CD4+ and CD8+ cells and subsets bearing specific markers of early activation. These included cells stained with fluorescein-conjugated monoclonal antibodies against interleukin-2 receptor (CD25+) and early activation marker (EAM+) (CD69+), and with fluorescein-conjugated peanut agglutinin (PNA+). Surprisingly, the injection of liposome-trapped STZ, at a 1/10 of the optimal dose only, induced a marked PLN enlargement comparable to the effect of optimal STZ dose. The effect of liposome-STZ could be dissociated from the non-drug-containing MLV-related lymphocyte activation. The data suggest several possible advantages from the introduction of chemicals by the liposome route and the subsequent PLN test for chemical-induced autoimmunity. Toxicological advantages could involve better control of chemical exposure, controlled exposure to the water-insoluble substances, drastic reduction of xenobiotic dose, a stronger, clear PLN response and possible elimination or at least restriction of false-negative results, due to the liposome adjuvancity. Overall, application of liposomes as an exposure route potentialized the STZ-induced early lymphocyte activation.
将脂质体包裹的链脲佐菌素(STZ)的淋巴细胞增殖潜力与局部注射到CD-1小鼠足垫中的生理盐水溶解的STZ的效果进行了比较。在STZ诱导的自身免疫样反应开始期间,监测腘窝淋巴结(PLN)肿大和淋巴细胞亚群的早期细胞活化。注射最佳STZ剂量(0.5 mg/足垫)可显著增加PLN绝对细胞数以及用荧光单克隆抗体染色的特异性辅助性T细胞(CD4+)、抑制性/细胞毒性T细胞(CD8+)和B细胞(Ig+)亚群。此外,带有早期活化特异性标志物的大/活化CD4+和CD8+细胞及亚群数量显著增加。这些细胞包括用抗白细胞介素-2受体(CD25+)和早期活化标志物(EAM+)(CD69+)的荧光素偶联单克隆抗体以及荧光素偶联花生凝集素(PNA+)染色的细胞。令人惊讶的是,仅以最佳剂量的1/10注射脂质体包裹的STZ,就可诱导出与最佳STZ剂量效果相当的显著PLN肿大。脂质体-STZ的作用可与不含药物的MLV相关淋巴细胞活化区分开来。数据表明,通过脂质体途径引入化学物质并随后进行PLN试验以检测化学诱导的自身免疫可能具有若干优势。毒理学优势可能包括更好地控制化学物质暴露、对水不溶性物质的可控暴露、大幅降低外源性物质剂量、更强、更明显的PLN反应以及由于脂质体佐剂作用可能消除或至少限制假阴性结果。总体而言,将脂质体作为一种暴露途径可增强STZ诱导的早期淋巴细胞活化。